CROaccess Alternative: One Platform for CRO and CDMO Sourcing

What CROaccess is: a verified review, August 2026

First, the disclosure: BioBridgeX publishes this comparison, and we compete with CROaccess for biotech sourcing traffic. To keep this page useful rather than promotional, every factual claim about CROaccess below comes from their own public pages, checked on 31 August 2026. Where something is not published, we say so instead of guessing.

CROaccess is a CRO marketplace built around a simple pitch: connect with CROs and purchase services, free for researchers. The buyer flow has three steps. You share your project through a simplified form rather than a formal RFP. Suppliers the site describes as vetted send proposals, which the company says can arrive within hours. Then you track milestones, budgets, and deliverables in one place. The company describes its matching as AI-driven RFP analysis over a curated network of specialized CROs, with a stated goal of moving from project definition to execution in days, not months.

The public directory at croaccess.com/allcros showed 288 CRO profiles when we checked, filterable by core services, technology and expertise, and location. Profiles range from small specialist labs like SauveBio and Alpha Preclinical to large recognizable names: ICON plc, Syngene International, Advarra, and Medpace Reference Laboratories all have profile pages. Six service categories organize the catalog: Pre-Clinical Research (29 services), Laboratory Services (19), Regulatory Services (12), Assay Development (8), Clinical Trials (4), and Toxicology Studies, which listed zero services on the day we looked.

Where CROaccess genuinely delivers

Credit where due. The free-for-researchers model is stated plainly on the site: researchers pay nothing to the platform and pay only the selected CRO for the services they buy. For an academic lab or an early discovery team that wants to find a CRO free of platform charges, that is exactly the right price.

The intake is genuinely low-friction. One form replaces a formal RFP, and the marketplace page promises competitive proposals you can compare on expertise, pricing, and timelines. Location filters span more than 100 cities worldwide, so geographic matching is real, not decorative.

Two other things stood out during our review:

• Recognizable supply. Profile pages for ICON plc, Syngene International, and Advarra sit alongside niche providers, so the network is not padded with shell listings.
• Operational ambition beyond sourcing. A sister product, CROprocure, offers procurement, accounts payable, and supplier management support for life science teams, which suggests the company understands lab operations pain past the first purchase order.

The gaps that matter when a molecule is heading to the clinic

The structural gap is manufacturing. None of CROaccess's six categories touch CMC, drug substance, drug product, or fill-finish, and its marketplace page makes no mention of CDMO services at all. The tell is Sharp Clinical Services: a clinical packaging and labeling specialist with a CROaccess profile, tagged only under "Clinical Operations & Trial Management" and "Logistics & Supply Chain" because no manufacturing category exists to put them in. If your program needs a GMP batch alongside its GLP package, you are back to cold emails for half the scope.

Depth is the second issue. Across all six categories the platform listed 72 services in total, and the Toxicology Studies category showed zero. That matters because GLP toxicology is usually the single largest line in an IND-enabling budget, and a sourcing platform that cannot return tox quotes leaves the most expensive part of your program unsourced.

The third issue is commercial transparency. What suppliers pay to be on CROaccess is not published anywhere we could find; the registration page offers CRO and Client tabs with no rate card. The Terms of Service page displayed placeholder text on the day we checked. And no company address or legal entity appears on the site. None of this is disqualifying for a young platform, but you should get answers in writing before routing a seven-figure program through any marketplace, theirs or ours.

How BioBridgeX works instead

BioBridgeX is a neutral marketplace operated by BioBridgeX Ltd in London. We run no labs, so there is no house CRO to steer your work toward. The public vendor directory lists more than 260 supplier profiles across CRO and CDMO categories, and you can browse it without creating an account.

The money model is published, and it is short. Buyers pay nothing. Suppliers pay a flat 2% success fee, charged only when a project is awarded and the supplier is paid. There are no listing fees, no subscriptions, and no pay-for-placement, so a supplier appears in your results because they fit your scope, not because they bought a slot.

Contracting is direct. You sign with the supplier, you pay the supplier, and your confidentiality terms sit between you and them. BioBridgeX coordinates the sourcing round and the quote comparison; it is not a party to your study contract.

One RFQ across CRO and CDMO scopes

An IND-enabling program is not a shopping list of lab services. Pharmacology and GLP toxicology hand off to bioanalysis; drug substance feeds the tox batch before it feeds the clinical batch; fill-finish and release testing gate your clinical timeline. When study sourcing lives on one platform and manufacturing sourcing lives in your inbox, those dependencies disappear from view until they bite.

BioBridgeX was built as a CDMO sourcing platform as much as a CRO one. Coverage discovery runs through CMC and manufacturing, so the same RFQ round can scope a GLP toxicology package and a fill-finish campaign, and you can see which suppliers cover adjacent steps before you fragment the program across vendors.

If the vendor taxonomy itself is the confusion, our CRO vs CDMO vs CMO guide sorts out which type of organization owns which part of your program in about ten minutes of reading.

Comparable quotes, not a stack of PDFs

CROaccess promises comparable proposals, and its marketplace page says you can compare expertise, pricing, and timelines. The mechanism behind that claim is not visible from the outside. What we can show you is ours: a structured RFQ in which every invited supplier answers the same line items, so quotes land as rows in a grid rather than as five differently formatted PDFs. Unit costs, timelines, and assumptions line up column by column, which is what makes a real head-to-head decision possible.

The supporting tools are free and work standalone, whether or not you ever run an RFQ with us: an RFP generator that turns your scope into a document suppliers can actually quote against, a quote comparison grid for normalizing bids you already have in hand, and an IND budget calculator for sanity-checking the total before you commit. Sourcing rounds on our side are invitation-based: suppliers are matched to your RFQ, so your time goes to reviewing real bids, not triaging an inbox.

Pricing and incentives, side by side

Both platforms are free for buyers, so the interesting comparison is the supplier side, because those economics shape what you see. CROaccess does not publish what CROs pay to participate. Its directory does mark some profiles as "Featured", so promoted placement exists in some form; what it costs and what it buys is not published.

BioBridgeX charges suppliers one thing: a flat 2% of the awarded project value, payable only after the supplier has won the work and been paid. On a $250,000 GLP toxicology package, that is a $5,000 fee, charged to the supplier, after they have your money. The incentive this creates is the one you want your sourcing platform to have: we earn nothing from listings, featuring, or the volume of introductions. We earn only when a match closes and gets paid, which pushes us to invite the suppliers most likely to win and deliver.

Which platform fits which team

A fair read of the evidence: if you are an academic lab or a discovery-stage team buying discrete services, CROaccess's live listings are exactly that shape (FACS services, exosome characterization, spatial biology profiling), the intake form takes minutes, and it costs you nothing. That is a reasonable place to start, and nothing stops you from browsing both directories before you commit to either.

If you are a biotech founder or program lead sourcing an IND-enabling package or a CMC scope, the calculus changes. You need CRO and CDMO quotes in one round, a toxicology bench that actually returns bids, structured comparison rather than proposal PDFs, and a fee model you can put in front of your board. That combination is what BioBridgeX was built for.

Evaluating the wider field? We publish the same style of verified comparison for Scientist.com and Science Exchange, with the same disclosure on each page: we write these comparisons, and we source every competitor claim from the public web.

Run your first sourcing round

Here is the whole process, from first look to award:

• Browse the public directory to check CRO and CDMO coverage before committing to anything
• Draft your scope with the free RFP generator, or bring your own protocol synopsis
• Submit your RFQ; matched suppliers are invited to quote against your exact line items
• Compare structured quotes side by side in the grid: prices, timelines, assumptions
• Award the work, contract directly with the supplier, and pay them directly; the 2% success fee is the supplier's, due only after they are paid

It is free for buyers, there is no subscription, and the directory is open before you register. Ready to see real numbers for your program? Compare quotes.